Wacker Biotech’s site in Halle, Germany will be expanded in the coming months into a competence center for actives based on messenger ribonucleic acid (mRNA).
CureVac is streamlining its external European manufacturing network for its mRNA product pipeline; having reassessed demand for its first-generation COVID-19 vaccine candidate.